Tharimmune granted european patent for delivery of optimized molecularly targeted therapeutics

Bridgewater, nj / accesswire / november 13, 2024 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that the european patent office intends to grant the company a patent covering biodegradable polymeric nanoparticles created for carrying therapeutic and targeting agents. with particular utility in cancer therapies, this innovative platform is designed to enhance the delivery of therapeutic antibodies and peptides, which are often limited by enzymatic degradation and poor systemic circulation.
THAR Ratings Summary
THAR Quant Ranking